PEDIATRIC HEMATOLOGY AND ONCOLOGY

Scope & Guideline

Transforming pediatric care with expert insights and research.

Introduction

Welcome to the PEDIATRIC HEMATOLOGY AND ONCOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of PEDIATRIC HEMATOLOGY AND ONCOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0888-0018
PublisherTAYLOR & FRANCIS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPEDIATR HEMAT ONCOL / Pediatr. Hematol. Oncol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

Pediatric Hematology and Oncology focuses on the comprehensive understanding and treatment of blood disorders and cancers in children. The journal aims to disseminate innovative research, clinical findings, and reviews that improve the knowledge and practices within this specialized field.
  1. Pediatric Hematology:
    Research on various hematological disorders affecting children, including anemia, sickle cell disease, and hemophilia, with an emphasis on pathophysiology, treatment modalities, and long-term outcomes.
  2. Oncological Studies:
    Focused studies on pediatric cancers, including leukemia, lymphoma, and solid tumors, exploring diagnosis, treatment strategies, clinical trials, and survivorship.
  3. Transplantation and Cellular Therapies:
    Investigation into hematopoietic stem cell transplantation and other cellular therapies as treatment options for pediatric patients with severe hematological malignancies.
  4. Genetic and Molecular Research:
    Studies examining the genetic underpinnings of pediatric diseases, including genetic disorders, cancer predisposition, and the role of molecular markers in treatment responses.
  5. Supportive Care and Quality of Life:
    Research addressing supportive care measures, psychosocial aspects, and quality of life outcomes for pediatric patients and their families throughout treatment and survivorship.
  6. International Health and Disparities:
    Exploration of the challenges and outcomes of pediatric hematology and oncology in low- and middle-income countries, focusing on access to care and treatment disparities.
The journal has seen a rise in interest in several innovative and critical areas of research that reflect the evolving landscape of pediatric hematology and oncology. These emerging themes are crucial in shaping future research directions and clinical practices.
  1. Precision Medicine and Genetic Testing:
    An increasing number of papers focus on the application of genetic testing and precision medicine approaches to tailor treatments for pediatric patients, indicating a significant trend towards personalized healthcare.
  2. Impact of COVID-19 on Pediatric Patients:
    Research examining the effects of the COVID-19 pandemic on pediatric hematology and oncology patients is on the rise, highlighting the need for understanding how global health crises affect care delivery and patient outcomes.
  3. Innovative Supportive Care Strategies:
    Emerging studies are focusing on supportive care interventions, including psychosocial support and palliative care, which are crucial for improving the quality of life for pediatric patients and their families.
  4. Long-Term Outcomes and Survivorship:
    There is a growing emphasis on the long-term health outcomes and survivorship issues faced by pediatric cancer survivors, reflecting a shift towards recognizing the importance of post-treatment quality of life.
  5. International Collaborative Research:
    An increase in multicenter and international studies indicates a trend towards collaborative research efforts, aiming to address global disparities in pediatric cancer care and outcomes.

Declining or Waning

While certain research areas continue to thrive, others appear to be declining in prominence within the journal. This may reflect shifting priorities in pediatric hematology and oncology or changes in research funding and interest.
  1. Traditional Chemotherapy Approaches:
    There seems to be a decrease in studies focusing solely on conventional chemotherapy regimens, as newer targeted therapies and immunotherapies gain more attention in the treatment of pediatric cancers.
  2. Single-Center Studies:
    A noticeable decline in the publication of single-center studies suggests a shift towards multicenter collaborations that provide broader data and insights into treatment outcomes.
  3. Basic Science and Laboratory Studies:
    Research papers focusing on basic science and laboratory methodologies appear to be waning as clinical applications and translational research take precedence, highlighting a move towards practical and immediate clinical relevance.

Similar Journals

Therapeutic Advances in Hematology

Fostering collaboration for a healthier tomorrow.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Turkish Journal of Hematology

Connecting researchers and clinicians to elevate hematology practices.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Blood and Lymphatic Cancer-Targets and Therapy

Illuminating the Path to Effective Cancer Interventions
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

AMERICAN JOURNAL OF HEMATOLOGY

Empowering Discoveries in Blood Disorders
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Elevating Hematology Research to New Heights
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Journal of Blood Medicine

Empowering Research: Your Gateway to Innovations in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

BONE MARROW TRANSPLANTATION

Empowering the Future of Bone Marrow Medicine.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Enhancing understanding, improving outcomes for young patients.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Egyptian Journal of Haematology

Empowering Hematologists with Cutting-Edge Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

ACTA HAEMATOLOGICA

Exploring the Depths of Hematology with Authority
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.